

Clinical Trial Protocol

Iranian Registry of Clinical Trials

16 Jul 2026

Evaluation of the effect of colchicine on the antithyroid antibody titer in chronic urticaria patient.

Protocol summary

Study aim

Determination of serum levels of Anti TPO and Anti Tg before starting treatment and 3 month after starting treatment with Colchicine in chronic urticaria patients
Record information about patient examinations based on the UAS7 and CU_Q2oL questionnaire before starting treatment and 3 month after starting treatment with Colchicine in chronic urticaria patients

Design

A double blind randomized clinical trial with parallel groups

Settings and conduct

50 patients with chronic urticaria will be considered as the study population referred to the allergy clinic of Imam Reza Clinic in Shiraz. Informational examinations of patients based on 2 standard questionnaires CU_Q2oL and UAS with questioner will be recorded in 2 steps (before the intervention, and 3 months after the intervention). Then, blood samples are taken from all patients with chronic urticaria , including Anti-TPO and Anti-TG serum levels (before the intervention, and 3 months after the intervention). Patients were randomly assigned to 2 groups based on their case number was even or odd, control group (standard treatment, including Fexofenadine and Doxepin) and the intervention group (including standard treatment + oral Colchicine at a dose of 1 mg daily for 3 months). The results will be recorded and finally compared with the results before the intervention.

Participants/Inclusion and exclusion criteria

Including patients with chronic urticaria with positive thyroid autoantibodies in the age range of 20 to 70 years ; excluding below 20 age, pregnant and lactating women, side effect of Colchicine

Intervention groups

The control group is treated with Fexofenadine and Doxepin for 3 months. The intervention group will receive Fexofenadine, Doxepin and Colchicine 1 mg for three months.

Main outcome variables

Reducing the title of autoantibodies and the symptoms of patients with urticaria after treatment with Colchicine

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20200406046967N1**

Registration date: **2020-04-10, 1399/01/22**

Registration timing: **prospective**

Last update: **2020-04-10, 1399/01/22**

Update count: **0**

Registration date

2020-04-10, 1399/01/22

Registrant information

Name

Masroor Babaeian

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 71 3649 9543

Email address

meisam.sargazi@zaums.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2020-05-04, 1399/02/15

Expected recruitment end date

2020-08-05, 1399/05/15

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date
empty

Scientific title
Evaluation of the effect of colchicine on the antithyroid antibody titer in chronic urticaria patient.

Public title
Effect of Colchicine in treatment of chronic urticaria

Purpose
Treatment

Inclusion/Exclusion criteria
Inclusion criteria:
 Patients with chronic urticaria in the age range of 20 to 70 years
Exclusion criteria:
 pregnant and lactating females Patients with Physical Urticaria and Vasculitis Urticaria Patients with Colchicine-induced drug side effects

Age
From **20 years** old to **70 years** old

Gender
Both

Phase
3

Groups that have been masked

- Participant
- Care provider
- Investigator
- Outcome assessor

Sample size
Target sample size: **50**

Randomization (investigator's opinion)
Randomized

Randomization description
This study is based on a Random number table. In this study, table numbers are read from above and to the right. Couples' numbers are for the first group (intervention) and individual numbers are for the second group (control).

Blinding (investigator's opinion)
Double blinded

Blinding description
Patients know that they are participating in the study and have entered the study consciously and with prior written consent, but do not know exactly which group they are in. The main researchers of the study are unaware of the type of medication used for each patient and how the patients are assigned to the groups and which group each patient is in. Data collection and follow-up officials are unaware of the type of medication used for each patient and how the patients are assigned to the groups and which group each patient is in.

Placebo
Not used

Assignment
Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics committee of Shiraz University of Medical Sciences

Street address

3rd floor., Niki 2 building., Ansar Ave., besat Blvd

City

Shiraz

Province

Fars

Postal code

7184684189

Approval date

2019-09-08, 1398/06/17

Ethics committee reference number

IR.SUMS.Med.Rec.1398.390

Health conditions studied

1

Description of health condition studied

Positive Autoantibody Chronic Urticaria

ICD-10 code

L50.1

ICD-10 code description

Idiopathic urticaria

Primary outcomes

1

Description

"Percentage of people with chronic urticaria who have autoimmune thyroiditis"

Timepoint

"Measurement of thyroid autoantibodies at the beginning of the study (before the intervention) and 3 months after taking colchicine"

Method of measurement

"Peripheral blood sample"

Secondary outcomes

1

Description

"The urticaria score in the Urticaria Activity Score 7 questionnaire"

Timepoint

"Comparison of the average total score of the Urticaria Activity Score 7 questionnaire in the study groups at the beginning of the study and 3 months after taking colchicine"

Method of measurement

" Urticaria Activity Score 7 questionnaire"

Email

motahari@sums.ac.ir

2**Description**

"The urticaria score in the Chronic Urticaria Quality of Life questionnaire"

Timepoint

Comparison of the average total score of the Chronic Urticaria Quality of Life questionnaire in the study groups at the beginning of the study and 3 months after taking colchicine"

Method of measurement

"Chronic Urticaria Quality of Life questionnaire"

Intervention groups**1****Description**

Intervention group: "The first intervention group of Fexofenadine tablets 120 mg once daily for 3 months from Saha Pharmaceuticals, Doxepin tablets 10 mg once daily for 3 months from Razak Pharmaceuticals and Colchicine tablets 1 mg once daily for 3 months from Modava Pharmaceuticals"

Category

Treatment - Drugs

2**Description**

Intervention group: "The second intervention group of Fexofenadine tablets 120 mg once daily for 3 months from Saha Pharmaceuticals, Doxepin tablets 10 mg once daily for 3 months from Razak Pharmaceuticals" ;

Category

Treatment - Drugs

Recruitment centers**1****Recruitment center****Name of recruitment center**

Emam Reza Clinic

Full name of responsible person

Masroor Babaeian

Street address

Imam Reza Specialized and Subspecialty Clinic, next to Namazi Hospital, Namazi Square

City

Shiraz

Province

Fars

Postal code

71473771348

Phone

+98 71 3212 7000

Fax

+98 71 3647 4673

Sponsors / Funding sources**1****Sponsor****Name of organization / entity**

Shiraz University of Medical Sciences

Full name of responsible person

Dr. Hesam Nabavi Zadeh

Street address

Pediatric's Department Office, Namazi Hospital, Namazi Square

City

Shiraz

Province

Fars

Postal code

7193613311

Phone

+98 71 3647 4332

Fax

+98 71 3647 4332

Email

nemazee_inf@sums.ac.ir

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Shiraz University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

Academic

Person responsible for general inquiries**Contact****Name of organization / entity**

Shiraz University of Medical Sciences

Full name of responsible person

Masroor Babaeian

Position

Resident

Latest degree

Specialist

Other areas of specialty/work

Immunology

Street address

3rd floor, Niki 2 building, Ansar 1 Ave, besat Blvd

City

Shiraz
Province
Fars
Postal code
7184684189
Phone
+98 71 3649 9543
Email
masroor.babaeian@yahoo.com

Person responsible for scientific inquiries

Contact

Name of organization / entity
Shiraz University of Medical Sciences
Full name of responsible person
Masroor Babaeian
Position
Resident
Latest degree
Specialist
Other areas of specialty/work
Immunology
Street address
3rd floor., Niki 2 building ., 1 Ansar Ave ., besat Blvd
City
Shiraz
Province
Fars
Postal code
7184684189
Phone
+98 71 3649 9543
Email
Masroor.babaeian@yahoo.com

Person responsible for updating data

Contact

Name of organization / entity
Shiraz University of Medical Sciences
Full name of responsible person
Masroor Babaeian
Position
Resident
Latest degree
Specialist

Other areas of specialty/work
Immunology
Street address
3rd floor., Niki 2 Building., 1Ansar Ave., Besat Blvd
City
Shiraz
Province
Fars
Postal code
7184684189
Phone
+98 71 3649 9543
Email
Masroor.babaeian@yahoo.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

Study Protocol

Yes - There is a plan to make this available

Statistical Analysis Plan

Yes - There is a plan to make this available

Informed Consent Form

Yes - There is a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

Yes - There is a plan to make this available

Data Dictionary

Yes - There is a plan to make this available

Title and more details about the data/document

All data can be shared after people have not been identified.

When the data will become available and for how long

Starting the access period 3 months after the publication of the results

To whom data/document is available

It will be available for researchers worker in academic and scientific institutions.

Under which criteria data/document could be used

they can provide jobs, university and reason of using data and articles.

From where data/document is obtainable

Email adress

What processes are involved for a request to access data/document

2 days

Comments